Blue Copper 5 PRIME Eye — Clinical Results

Clinical Results

Blue Copper 5 PRIME Eye

Every active in PRIME Eye is clinically dosed — checked against its own clinical study before it earns a place. Here is the evidence.

What users saw in 4 weeks

Before
Before using Blue Copper 5 PRIME Eye
After 4 weeks
After 4 weeks of Blue Copper 5 PRIME Eye

Photography of an individual user following twice-daily use for 4 weeks. Individual results vary.

94%

saw a lifted, firmer eye area

94%

saw reduced crow’s feet

96%

said dark circles looked reduced

100%

said their eyes looked more awake

Consumer perception study over 4 weeks of twice-daily use.

The ingredient evidence

Matrikine peptide complex

Clinically dosed — an exact match to the studied level

The matrikine peptide duo that signals the skin to rebuild collagen. PRIME Eye carries it at the same concentration used in the clinical study below.

Clinical result vs placebo (2 months) Figure
Surface area occupied by deep wrinkles (>200µm) -44.9%
Main wrinkle density -37.0%
Average wrinkle depth -15.1%
Skin tone +19.5%

Method: Two panels of 23 volunteers aged 39–74; half-face, placebo-controlled, twice daily for 2 months; confocal analysis of silicone skin imprints. A separate 4-month study (two panels of 30 volunteers) recorded -27% average wrinkle depth. Supplier clinical study of the ingredient; not conducted on the finished Osmotics product.

Laboratory evidence

In-vitro, same dossier

In fibroblast cultures, the same peptide complex significantly increased the synthesis of the skin’s core structural proteins.

Protein synthesis Increase
Collagen I +258%
Hyaluronic acid +179%
Fibronectin +164%

Method: In-vitro fibroblast culture study by the ingredient manufacturer. Laboratory results; not a measure of results on human skin.

Firming peptide (acetyl tetrapeptide-2)

Clinically dosed — an exact match to the studied level

A firming peptide that works against gravity — increasing collagen and functional elastin synthesis and reinforcing the focal adhesions that hold skin cells together, helping keep the delicate eye-area skin taut. PRIME Eye carries it at its clinically studied dose.

Clinical result (56 days) Figure
Skin firmness (reduced maximal deformation) +25.2%
Overall skin elasticity +16%

Method: Women aged 40–60 with sagging skin and loss of elasticity; twice daily for 56 days. Visible lifting of the facial contour also recorded. Supplier clinical study of the ingredient; not conducted on the finished Osmotics product.

Eye-contour active (Beautifeye®)

At its studied use level

A botanical eye active (Albizia julibrissin bark extract with darutoside) that targets the drooping, hooded look of the upper lid, smooths crow’s-feet and fades the redness behind dark circles.

Clinical result vs placebo (2 months) Figure
Drooping eyelid surface -61%
Eyelid fold height (less hooded) -91%
Crow’s-feet wrinkle volume -34%
Crow’s-feet wrinkle depth -33%
Dark-circle redness -32%

Method: 24 women (mean age 60, 40–79) with upper-eyelid folds and crow’s-feet applied a cream containing 3% of the active twice daily for 2 months, vs placebo. Supplier clinical study of the ingredient; not conducted on the finished Osmotics product.

The confirmed peptide stack

Every active checked against the batch formula

Unlike most eye creams, every active in PRIME Eye is present at its supplier-recommended working concentration — verified against our manufacturing formula, not estimated from an ingredient list. The concentrations themselves are proprietary; what we publish is that each one clears the bar.

Active Clinically dosed
Matrikine peptide complex — collagen signalling
Eye-contour active (Beautifeye®) — lift, crow’s-feet, dark circles
Firming peptide (acetyl tetrapeptide-2)
The Blue Copper peptide

Doses confirmed against the quantitative manufacturing formula and the suppliers’ published use levels; the formula itself is proprietary.

Blue Copper peptide

Pioneered by Osmotics in 1998

Copper peptides are among the most-studied molecules in skin science, with peer-reviewed research since 1988 showing they stimulate collagen synthesis in fibroblasts and support the skin’s natural repair processes.

References: Maquart et al., FEBS Letters, 1988; Pickart & Margolina, Cosmetics, 2017.